SOL – Morgans rates the stock as Hold
The Hold rating and $28.84 target are unchanged while the analyst awaits the proposed vote on the merger in mid-September.
Read MoreBroker News
STO – UBS rates the stock as Buy
UBS retains a Buy rating and $8.30 target.
Read MoreCCX – Citi rates the stock as Neutral
The broker maintains a Neutral rating, noting the stock appears to be factoring in the upside. Target is $4.30.
Read MoreAUA – Morgans rates the stock as Add
Morgans initiates coverage on Audeara with a Speculative Buy rating and target price of $0.33.
Read MoreSDF – Macquarie rates the stock as Outperform
Outperform rating and $4.70 price target are retained.
Read MoreAST – Credit Suisse rates the stock as Neutral
Neutral maintained. Target is reduced to $1.75 from $1.95.
Read MoreVCX – Credit Suisse rates the stock as Neutral
The analysts underlying earnings estimates are unchanged and the Neutral rating and $1.69 target are unchanged.
Read MoreMLG – Morgans rates the stock as Hold
Morgans initiates coverage of MLG Oz with a $1.08 target and a Hold rating, while awaiting greater visibility after recent setbacks in the crushing business.
Read MoreSWM – UBS rates the stock as Buy
The analyst lifts the FY21 EPS forecast by 9% and maintains the Buy rating and $0.60 price target.
Read MoreARF – Credit Suisse rates the stock as Neutral
Neutral retained. Target is raised to $3.23 from $3.04.
Read MoreCOL – Morgans rates the stock as Add
The Add rating is maintained and the target is decreased to $17.80 from $18.50.
Read MoreCQR – Macquarie rates the stock as Outperform
The broker sees upside risk to shopping centre valuations and retains Outperform. Target rises to $4.18 from $4.04.
Read MoreIAG – UBS rates the stock as Buy
With the stop-lost not likely to be renewed into FY22, the broker expects the company will face a sharp increase in its natural perils budget next year. Buy rating and $6 target retained.
Read MoreSCP – Credit Suisse rates the stock as Neutral
The broker revises FY22 and FY23 estimates up to reflect the Marketown and Raymond Terrace acquisitions. Neutral maintained. Target rises to $2.54 from $2.50.
Read MoreASB – Citi rates the stock as Buy
Citi maintains a Buy rating. Target is raised to $3.35 from $3.30. Citi also asserts the ASIC lawsuit is not a material headwind, noting the maximum financial penalty is likely to be $1-2m.
Read MoreCGF – Credit Suisse rates the stock as Neutral
Ahead of the investor briefing, Credit Suisse reiterates a Neutral rating and $6.05 target.
Read MoreCOL – Macquarie rates the stock as Upgrade to Outperform
The stock screens attractively on valuation and the broker switches its preference to staples, upgrading to Outperform from Neutral. Target is raised to $18.20 from $17.30.
Read MoreIRE – Morgans rates the stock as Hold
The analyst makes no changes to forecasts. The target price lifts to $11.37 from $10.95 after a valuation roll forward.
Read MorePMV – Credit Suisse rates the stock as Neutral
Uncertainty with respect to the short-term performance supports the broker’s decision to retain a Neutral rating. Target is raised to $26.70 from $25.05.
Read MoreREG – Morgans rates the stock as Upgrade to Add
Morgans lifts the rating for Regis Healthcare to Add from Hold. The target price increases to $2.23 from $2.03.
Read MoreIEL – UBS rates the stock as Buy
Buy rating is maintained with the target lowered to $28.25 from $29.05.
Read MoreALU – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price increases to $42.00 from $35.00.
Read MoreNHC – Macquarie rates the stock as Downgrade to Neutral
Macquarie downgrades New Hope to Neutral from Outperform following recent strength in the share price. Target is raised to $1.70 from $1.50.
Read MoreCOL – Credit Suisse rates the stock as Outperform
The broker retains an Outperform rating and $18.19 target.
Read MoreCHN – Macquarie rates the stock as Outperform
The Outperform rating is maintained, while the target price rises to $9.90 from $9.20.
Read MoreAX1 – Morgans rates the stock as Hold
The target price is increased to $2.85 from 2.55 and the Hold rating is unchanged.
Read MoreRHC – Credit Suisse rates the stock as Neutral
Neutral rating with a $70 target price maintained.
Read MoreGNC – UBS rates the stock as Buy
UBS retains a Buy rating based on increased crop assumptions for FY22 and the potential for capital management. Target is $6.70.
Read MoreWOW – Credit Suisse rates the stock as Downgrade to Underperform
The rating is downgraded to Underperform from Neutral, largely on valuation, while the target is lowered to $37.98 from $38.05.
Read MoreSLC – Morgans rates the stock as Add
Add rating and target rises to $1.33 from $1.27.
Read MoreA2M – Citi rates the stock as Sell
Sell and $5.85 target retained.
Read MoreIGO – Macquarie rates the stock as Outperform
Macquarie prefers Nickel Mines, IGO Ltd and Western Areas for nickel production. The Lighten rating and $8.50 target are retained.
Read MoreASX – Morgans rates the stock as Downgrade to Reduce
The rating falls to Reduce from Hold, due to the recent share price rise. The target price increases to $65.87 from $65.59.
Read MoreTRS – Morgans rates the stock as Add
The analyst lowers EPS forecasts for FY21-23 by -25%, -17% and -11%, respectively. The target price falls to $6.80 from $8.91 and the Add rating is maintained.
Read MoreASX – UBS rates the stock as Neutral
Neutral rating and $70 target maintained.
Read MoreAFG – Morgans rates the stock as Add
The add rating and $2.90 target are unchanged.
Read MoreMP1 – UBS rates the stock as Buy
While remaining positive, UBS requires a sign that the new sales initiatives are in place and driving stronger port growth. Buy rating and $17.10 target maintained.
Read MoreCWY – Credit Suisse rates the stock as Downgrade to Underperform
The broker downgrades to Underperform from Neutral. Target is reduced to $2.40 from $2.50.
Read MoreFMG – Morgans rates the stock as Downgrade to Reduce
Morgans lowers the rating for Fortescue Metals Group to Reduce from Add and decreases the target price to $18.70 from $21.10.
Read MoreWES – Credit Suisse rates the stock as Neutral
The broker retains a Neutral rating and lowers the target to $57.23 from $57.32 after a few minor adjustments to chemicals forecasts.
Read More
